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Idiopathic hyperammonemia (IHA) is characterfized by an abrupt alteration in mental status asfsociated with markedly elevated plasma ammonia 
levels in the absence of any identifiable causes. It fref
quently results in intractable coma and is associated 
with high mortality.1 It has been reported in some 
patients with hematological malignancy after receivf
ing intensive chemotherapy, following bone marrow 
transplantation, or after using 5ffluorouracil for some 
solid tumors.2 Cytarabine, daunomycin, cyclophosphaf
mide, vincristine, amsacrine, etoposide, asparaginase, 
busulfan, and methotraxate,, all used for treating hef
matological malignancies, have been associated with 
idiopathic hyperammonemia.1f3 No previous reports 
have described the association between idiopathic 
hyperammonemia and combined chemotherapy with 
vinorelbine, topotecan, and cisplatin. We describe a 
case of a patient with acute lymphocytic leukemia that 
developed acute idiopathic hyperammonemia after ref
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idiopathic hyperammonemia (iha) had been reported in some patients with hematological malignancy 
after receiving intensive chemotherapy, following bone marrow transplantation, or after using 5-fluoro-
uracil for some solid tumors. the chemotherapeutic agents involved include cytarabine, daunomycin, 
cyclophosphamide, vincristine, amsacrine, etoposide, asparaginase, busulfan, and methotraxate, all used 
for treating hematological malignancies. no previous reports have described the association between 
idiopathic hyperammonemia and combined chemotherapy with vinorelbine, topotecan, and cisplatin. 
We describe a 20-year-old girl with normal liver function and relapsed precursor b-lymphoblastic leuke-
mia receiving the modified tVtG (topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine) 
protocol to control her disease. We used cisplatin (30 mg/m2/day) to replace thiotepa on day 3 because 
thiotepa was not available in taiwan. the patient developed acute idiopathic hyperammonemia after 5 
days of chemotherapy and died 9 days after chemotherapy. to our knowledge, this patient is the first re-
port of the association of hyperammonemia and chemotherapy with vinorelbine, topotecan, and cisplatin 
in the english literature. 
ceiving chemotherapy with vinorelbine, topotecan, and 
cisplatin.
CASE
A 20fyearfold female had precursor Bflymphoblastic 
leukemia that resulted in complete remission after ref
ceiving intensive induction chemotherapy with doxoruf
bicin, vincristine and asparaginase basedfchemotherapy 
in April 2008. Otherwise, the patient had no personal 
or family history of liver disease. Furthermore, she did 
not consume alcohol on a regular basis. Her medicaf
tions did not include hepatotoxic agents such as acetf
aminophen, salicylates, valproate, and carbamazepine. 
Unfortunately, her disease relapsed and she was in ref
fractory status even after allogeneic peripheral blood 
stem cell transplantation in July 2008. Salvage chemof
therapy with highfdose cytarabine and mitoxantrone, 
followed by donor lymphocyte infusion had been used 
to control her disease but the response was poor. In 
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December 2008, she received the salvage combination 
chemotherapy for her refractory disease. The regimen 
was modified from the Memorial SloanfKettering 
Cancer Center TVTG (topotecan, vinorelbine, thiof
tepa, dexamethasone, and gemcitabine) protocol. The 
TVTG protocol consists of topotecan (1 mg/m2/day) 
from day 2 to 6, vinorelbine (20 mg/m2/day) on day 1, 
8, 15 and 22, thiotepa (15 mg/m2/day) on day 3, gemf
citabine (10 mg/m2/min over 6 hours; total dose 3600 
mg/m2/dose) on day 8, and dexamethasone (45 mg/
m2/day) from day 8 to 15.4 We used cisplatin (30 mg/
m2/day) to replace thiotepa on day 3 because thiotepa 
was not available in Taiwan. The doses of chemotheraf
py, Glasgow coma scale and relevant laboratory values 
over time in this patient are shown in Table 1.
The patient’s liver function was normal before the 
TVTG chemotherapy. She had neither HBV nor HCV 
infection before. Impaired liver function was found on 
day 2 of chemotherapy, but it improved progressively 
thereafter. Neutropenia was found on day 2 of chemof
therapy. The chemotherapy had only been administered 
for 5 days and was withdrawn on day 6 because the 
patient became drowsy and disorientated on that day. 
She could neither recognize her family nor obey orders. 
Thus, she did not receive the fifth dose of topotecan nor 
gemcitabine. Her serum ammonia level was 266 µg/dL 
(normal range 5f69 µg/dL) on day 6. Emergent brain 
CT without contrast medium showed no significant 
intracranial abnormality, such as hemorrhage, brain 
mass, or brain edema. Lactulose was prescribed for her 
hyperammonemia. Ammoniaftrapping agents, such as 
sodium benzoate and phenylacetate, were not available 
at our hospital. A low protein diet was prescribed. Her 
consciousness level further deteriorated on day 7. Brain 
MRI on that day showed no brain infarction or brain 
edema. Arterial blood gas measurement revealed respif
ratory alkalosis (pH 7.51, pCO2 20 mmHg, pO2 84 
mmHg with 3 liter of oxygen per minute applied by face 
Table 1. Doses of chemotherapy, Glasgow coma scale and laboratory values in patient with idiopathic hyperammonemia.
Day 1 2 3 4 5 6 7 8 9
Doses of the 
chemotherapy
Vinorelbine
30 mg
Topotecan
1.5 mg
Topotecan
1.5 mg,
Cisplatin
45 mg
Topotecan
1.5 mg
Topotecan
1.5 mg
Glasgow coma 
scale E4V5M6 E4V5M6 E4V5M6 E4V5M6 E4V5M6 E4V4M5
E3V2M3
E1V1M1
E1VtM1 E1VtM1
White blood cells 
(per μL) 1470 700 540 210 160 500
Hemoglobin
(g/dL) 8.5 7.8 9.0 8.4 9.2 9
platelets 
(1000/μL) 13 59 35 107 74 11
Ammonia
(5-69 μg/dL) 266 347 642 2249
ALT (0-40 iU/L) 204 108 77 36
AST (5-45 iU/L) 128 32 14 84
Total bilirubin 
(0.2-1.6 mg/dL) 0.26 0.33 0.67 0.29
ALp (10-100 U/L) 83 92 81
GGT (4-51 U/L) 80 83 71
pT (iNr) 1.04
ApTT (second) 30.2
Albumin 
(3.7-5.3 g/dL) 3
BUN (7-20 mg/dL) 13 6
Creatinine 
(0.5-1.2mg/dL) 0.38 0.51
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mask, HCO3f 16 mmol/L). A seizure occurred and the 
Glasgow coma scale became E1V1M1 in the afternoon 
on day 7. Midazolam and phenytoin were administered to 
suppress seizures. A lumbar puncture showed an opening 
pressure of 180 mmH2O. The WBC count of the ceref
brospinal fluid (CSF) was 2/µL. The CSF protein was 42 
mg/dL and glucose was 108 mg/dL (serum glucose 117 
mg/dL). Cytology showed no malignant cells. Culture 
for bacteria, tuberculosis, and fungus were all negative. 
The ammonia level increased rapidly. Her family ref
fused hemodialysis for treating hyperammonemia and 
a liver biopsy for confirming the cause of hyperammof
nemia due to her severe illness. She died on day 9 after 
chemotherapy.
DISCUSSION
Idiopathic hyperammonemia (IHA) was first reported 
in the 1980s as a complication of treatment for acute 
leukemia.1 It has been defined as a plasma ammonia 
level greater than twice the upper limit of normal, with 
relatively normal liver function tests, and in the absence 
of other identifiable causes (Table 2).1, 5f7 Our patient 
did not have a history of taking drugs that could pof
tentially cause hyperammonemia. Although her liver 
function was abnormal during the initial days of chef
motherapy, it improved when hyperammonemia was 
found. Furthermore, there was no evidence of hepatic 
failure among the other relevant laboratory data. The 
patient did not previously have episodes of disturbance 
of consciousness or hyperammonemia. Inborn errors of 
metabolism (IEMs) involving the urea cycle may lead 
to hyperammonemia, but these defects usually cause 
symptoms during infancy and childhood. Occasionally, 
certain urea cycle disorders and other defects of amino 
acid metabolism or fatty acid oxidation may present in 
previously healthy adults. Among urea cycle disorders, 
ornithine transcarbamylase (OTC) deficiency most 
commonly presents in adulthood. OTC deficiency is an 
Xflinked disease and affects male infants. Rarely, female 
carriers may be predisposed to develop hyperammonef
mia during pregnancy, the postpartum period, infecf
tions, or parenteral nutrition.8,9 IEMs could be ruled out 
in our patient because the analysis of serum and urine 
amino acids were within normal limits. Otherwise, our 
patient was not fasting and did not receive parenteral 
nutrition. Before coma, her oral intake was fair. After 
her mental status altered, nasogastric feeding was done. 
There were no evidence of gastrointestinal bleeding, 
urinary tract infection, pneumonia, bacteremia, or tuf
mor lysis syndrome (serum potassium, phosphate, and 
uric acid were within normal limits) in this patient. Her 
renal function was normal. She did not have constipaf
Table 2. Differential diagnosis of hyperammonemia in critically ill 
adults.5,7
Increased ammonia production
  •  infections with urease-producing bacteria (Proteus, 
     Klebsiella species)
  •  increased protein catabolism
      - Gastrointestinal bleeding
      - Burns or trauma
      - Corticosteroids
      - Starvation
      - Total parenteral nutrition
  •  Cancer (esp. multiple myeloma)
  •  Chemotherapy (asparaginase, 5-FU, cytarabine)
Decreased ammonia excretion
  •   Acute liver failure
  •  Cirrhosis
      - Transjugular intrahepatic portosystemic shunt (TipS)
   •  inborn errors of metabolism
      - Ornithine transcarbamylase deficiency
      - Other urea cycle disorders
      - Organic acidemias
      - Fatty acid oxidation defects
Drug-induced hyperammonemia
   •  Drug-induced acute hepatic failure 
          (acetaminophen, HMG-CoA reductase inhibitor, 
          halothane, anti-tuberculous agents, nonsteroidal 
          antiinflammatory drugs, antibiotics, antifungals, etc.)
   •  Salicylates (reye’s syndrome)
   •  Drugs affecting urea cycle enzymes (valproate, 
      carbamazepine, sulfadiazine/pyrimethamine)
   •  Drugs leading to increased ammonia production (glycine)
Idiopathic hyperammonemia
tion. After exclusion of the potential causes of hyperf
ammonemia, she was diagnosed as having IHA.
The clinical manifestations of IHA are lethargy, 
confusion, weakness, incoordination, and encephalopaf
thy, which may progress to seizure, coma, and death. 
Increased intracranial pressure and diffuse cerebral 
edema are commonly found. Almost all patients have 
profound neutropenia. Respiratory alkalosis is also a 
feature.1 Our patient had symptoms and signs of acute 
hyperammonemia, with progressive lethargy, seizure, 
coma, profound neutropenia, and respiratory alkalosis 
although intracranial pressure was not elevated on lumf
bar puncture and no brain edema was revealed by brain 
CT and MRI. 
IHA has been reported after intensive chemotherapy 
in patients with leukemia, in patients undergoing bone 
marrow transplantation, in patients with solid tumors 
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treated with continuous infusions of 5ffluorouracil, and 
in patients undergoing lung transplantation.5 The incif
dence of IHA in patients receiving chemotherapy for 
acute leukemia is poorly defined because less than 30 
cases have been described in the literature. Cytarabine, 
daunomycin, cyclophosphamide, vincristine, amsaf
crine, etoposide, asparaginase, busulfan, and methotf
raxate have been reported to be associated with IHA in 
patients with hematological malignancies.1f3 Our case 
received vinorelbine, topotecan, and cisplatin before 
the onset of hyperammonemia. Her acute hyperamf
monemia was most likely associated with vinorelbine, 
topotecan, and cisplatin. To our knowledge, there are 
no previous reports mentioning the association bef
tween IHA and vinorelbine, topotecan, and cisplatin 
in the English literature. This case serves as a reminder 
that physicians should carefully monitor the symptoms 
and signs of idiopathic hyperammonemia when these 
agents are used in their patients.
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